Moleculin reports interim results from MIRACLE trial in r/r AML patientsWorldPharmaceuticals·9 hours agoMBRX+2.50%
12 Health Care Stocks Moving In Friday's Intraday Sessionbenzinga_article·Jul 31 at 12:05 PMMBRX+2.50%NUWE-5.11%
Moleculin Biotech prices offering with warrants for 37,130,001 shares at $0.75 exercise pricePUBT·Jul 31 at 09:12 AMMBRX+2.50%
Moleculin Biotech Highlights Promising MIRACLE Trial Remission DataTip Ranks·Jul 31 at 07:34 AMMBRX+2.50%
12 Health Care Stocks Moving In Friday's Pre-Market Sessionbenzinga_article·Jul 31 at 07:05 AMNUWE-5.11%REPL+10.00%
Moleculin says MIRACLE trial posts 37% interim CRc rate in venetoclax-failed AML patientsPUBT·Jul 31 at 07:05 AMMBRX+2.50%
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga_article·Jul 29 at 12:06 PMAVTR-1.05%MBRX+2.50%
Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment | MBRX Stock NewsStockTitan·Jul 5 at 11:33 PMMBRX+2.50%
